- Balakrishnan, Ilango;
- Danis, Etienne;
- Pierce, Angela;
- Madhavan, Krishna;
- Wang, Dong;
- Dahl, Nathan;
- Sanford, Bridget;
- Birks, Diane K;
- Davidson, Nate;
- Metselaar, Dennis S;
- Meel, Michaël Hananja;
- Lemma, Rakeb;
- Donson, Andrew;
- Vijmasi, Trinka;
- Katagi, Hiroaki;
- Sola, Ismail;
- Fosmire, Susan;
- Alimova, Irina;
- Steiner, Jenna;
- Gilani, Ahmed;
- Hulleman, Esther;
- Serkova, Natalie J;
- Hashizume, Rintaro;
- Hawkins, Cynthia;
- Carcaboso, Angel M;
- Gupta, Nalin;
- Monje, Michelle;
- Jabado, Nada;
- Jones, Kenneth;
- Foreman, Nicholas;
- Green, Adam;
- Vibhakar, Rajeev;
- Venkataraman, Sujatha
Diffuse intrinsic pontine glioma (DIPG) is an incurable brain tumor of childhood characterized by histone mutations at lysine 27, which results in epigenomic dysregulation. There has been a failure to develop effective treatment for this tumor. Using a combined RNAi and chemical screen targeting epigenomic regulators, we identify the polycomb repressive complex 1 (PRC1) component BMI1 as a critical factor for DIPG tumor maintenance in vivo. BMI1 chromatin occupancy is enriched at genes associated with differentiation and tumor suppressors in DIPG cells. Inhibition of BMI1 decreases cell self-renewal and attenuates tumor growth due to induction of senescence. Prolonged BMI1 inhibition induces a senescence-associated secretory phenotype, which promotes tumor recurrence. Clearance of senescent cells using BH3 protein mimetics co-operates with BMI1 inhibition to enhance tumor cell killing in vivo.